A suit against Janssen Pharmaceuticals over the blood thinner Xarelto is making novel claims that, if taken only once a day, the medication might not be effective for a full 24 hours.
The new claims were filed separately from the ongoing mass-tort program in the Philadelphia Court of Common Pleas that focuses on allegations that the anticoagulant causes uncontrollable bleeding. But, according to the plaintiffs’ attorneys and others practicing in the products liability field, a significant number of plaintiffs could soon begin looking into filing similar claims.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
